Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials (vol 34, pg 1327, 2017)

Por: Adsit, S, Zaldivar, ER, Sofen, H, Dei-Cas, I, Maldonado-Garcia, C, Penaranda, EO, Puig, L, Meng, XY, Fox, T, Guana, A

---

Publicada: 1 jul 2017

---

---

Filiaciones:
Adsit, S:
 TCR Med Corp, San Diego, CA 92123 USA

Zaldivar, ER:
 Dermos, Guatemala City, Guatemala

Sofen, H:
 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

Dei-Cas, I:
 Halitus, Buenos Aires, DF, Argentina

Maldonado-Garcia, C:
 Ctr Dermatol Dr Ladislao de la Pascua, Mexico City, DF, Mexico

Penaranda, EO:
 Riesgo de Fractura SA, Bogota, Colombia

Puig, L:
 Univ Autnoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

Meng, XY:
 Novartis Pharmaceut, E Hanover, NJ USA

Fox, T:
 Novartis Pharma AG, Basel, Switzerland

Guana, A:
 Novartis Pharmaceut, E Hanover, NJ USA